600056 中国医药
交易中 07-29 13:52:12
资讯
新帖
简况
中国医药（600056）披露向关联方出租美康大厦事项，7月28日股价下跌0.43%
证券之星 · 07-28 22:19
中国医药（600056）披露向关联方出租美康大厦事项，7月28日股价下跌0.43%
每周股票复盘：中国医药（600056）子公司获布美他尼注射液批件
证券之星 · 07-26
每周股票复盘：中国医药（600056）子公司获布美他尼注射液批件
股市必读：中国医药（600056）7月23日董秘有最新回复
证券之星 · 07-24
股市必读：中国医药（600056）7月23日董秘有最新回复
中国医药（600056）披露子公司获得药品补充申请批准通知书，7月20日股价上涨1.59%
证券之星 · 07-20
中国医药（600056）披露子公司获得药品补充申请批准通知书，7月20日股价上涨1.59%
每周股票复盘：中国医药（600056）子公司获依折麦布原料药批文
证券之星 · 07-19
每周股票复盘：中国医药（600056）子公司获依折麦布原料药批文
中国医药(600056.SH)子公司化学原料药依折麦布上市申请获批
智通财经 · 07-16
中国医药(600056.SH)子公司化学原料药依折麦布上市申请获批
2025年度中国医药工业营收百强榜发布，齐鲁制药连续三年位列第三
蓝鲸财经 · 07-13
2025年度中国医药工业营收百强榜发布，齐鲁制药连续三年位列第三
美银证券：授权交易活跃料推动中国医药板块估值重评 上调信达生物(01801)目标价119.2港元
智通财经 · 07-10
美银证券：授权交易活跃料推动中国医药板块估值重评 上调信达生物(01801)目标价119.2港元
瑞银：中国医药零售行业监管影响有限 降阿里健康(00241)目标价 维持京东健康(06618)的“买入”评级
智通财经 · 07-06
瑞银：中国医药零售行业监管影响有限 降阿里健康(00241)目标价 维持京东健康(06618)的“买入”评级
股市必读：中国医药（600056）7月3日董秘有最新回复
证券之星 · 07-06
股市必读：中国医药（600056）7月3日董秘有最新回复
股市必读：中国医药（600056）7月1日董秘有最新回复
证券之星 · 07-02
股市必读：中国医药（600056）7月1日董秘有最新回复
仁和药业：引进外资共同开发创新药是当前中国医药产业从“跟随创新”向“源头创新”跃升的关键路径
证券之星 · 06-24
仁和药业：引进外资共同开发创新药是当前中国医药产业从“跟随创新”向“源头创新”跃升的关键路径
太极集团：公司实际控制人中国医药集团有限公司间接持有公司30.12%的股份
证券之星 · 06-22
太极集团：公司实际控制人中国医药集团有限公司间接持有公司30.12%的股份
每周股票复盘：中国医药（600056）拟每股派现0.07525元
证券之星 · 06-20
每周股票复盘：中国医药（600056）拟每股派现0.07525元
中国医药（600056）披露2025年年度权益分派实施公告，6月17日股价上涨0.22%
证券之星 · 06-17
中国医药（600056）披露2025年年度权益分派实施公告，6月17日股价上涨0.22%
中国医药最新公告：子公司天方药业获阿哌沙班原料药上市批准
证券之星 · 06-08
中国医药最新公告：子公司天方药业获阿哌沙班原料药上市批准
艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌
智通财经网 · 06-04
艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌
股市必读：中国医药（600056）6月2日董秘有最新回复
证券之星 · 06-03
股市必读：中国医药（600056）6月2日董秘有最新回复
中国医药：公司目前经营正常
证券之星 · 06-02
中国医药：公司目前经营正常
每周股票复盘：中国医药（600056）子公司卡络磺钠注射液通过一致性评价
证券之星 · 05-31
每周股票复盘：中国医药（600056）子公司卡络磺钠注射液通过一致性评价
加载更多
公司概况
公司名称：
中国医药健康产业股份有限公司
所属行业：
批发业
上市日期：
1997-05-15
主营业务：
中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是化学制剂、诊断药品及试剂、医用耗材、医疗器械、特医产品、医美产品、中成药、中药饮片、配方颗粒、生物制剂、营养保健品。
发行价格：
7.02
{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"中国医药","latestPrice":9.5,"timestamp":1785304332000,"preClose":9.35,"halted":0,"volume":11639880,"delay":0,"changeRate":0.016,"floatShares":1495000000,"shares":1496000000,"eps":0.327,"marketStatus":"交易中","change":0.15,"latestTime":"07-29 13:52:12","open":9.38,"high":9.51,"low":9.35,"amount":110000000,"amplitude":0.0171,"askPrice":9.5,"askSize":1306,"bidPrice":9.49,"bidSize":762,"shortable":0,"etf":0,"ttmEps":0.327,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1785308400000},"marketStatusCode":2,"adr":0,"adjPreClose":9.35,"symbolType":"stock","openAndCloseTimeList":[[1785288600000,1785295800000],[1785301200000,1785308400000]],"highLimit":10.29,"lowLimit":8.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"isCdr":false,"pbRate":1.16,"roa":"--","peRate":29.051988,"roe":"1.53%","epsLYR":0.3164,"committee":-0.21787,"marketValue":14211000000,"turnoverRate":0.0078,"status":0,"floatMarketCap":14206000000},"requestUrl":"/m/hq/s/600056","defaultTab":"news","newsList":[{"id":"2654488878","title":"中国医药（600056）披露向关联方出租美康大厦事项，7月28日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654488878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654488878?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:19","pubTimestamp":1785248355,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，中国医药报收于9.35元，较前一交易日下跌0.43%，最新总市值为139.86亿元。近日，中国医药健康产业股份有限公司披露第十届董事会第5次会议决议公告。公告显示，公司下属全资子公司中国医保拟与关联方康养公司签署《补充协议》，将美康大厦租赁期限调整为2026年7月1日至2029年6月30日，年租金1,047.25万元，租赁期内租金总额不超过3,141.75万元。该事项构成关联交易，关联董事已回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0185","BK0250","BK0010","BK0188","BK0082","BK0028","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052292","title":"每周股票复盘：中国医药（600056）子公司获布美他尼注射液批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052292","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654052292?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:52","pubTimestamp":1785001936,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，中国医药报收于9.2元，较上周的9.46元下跌2.75%。本周关注点公司公告汇总：子公司天方药业获批布美他尼注射液上市许可变更公司公告汇总中国医药全资子公司天方药业有限公司收到国家药监局核准签发的布美他尼注射液《药品补充申请批准通知书》，药品上市许可持有人变更为天方药业，批准文号不变，生产场地、处方、生产工艺及质量标准与原药品一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0175","BK0188","BK0010","BK0028","BK0185","BK0082","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653720812","title":"股市必读：中国医药（600056）7月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653720812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653720812?lang=zh_cn&edition=full","pubTime":"2026-07-24 02:14","pubTimestamp":1784830454,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，中国医药报收于9.44元，上涨0.11%，换手率1.11%，成交量16.57万手，成交额1.56亿元。董秘最新回复投资者： 1.请问公司投资者问答什么时候可以恢复正常?公司严格按照监管要求履行信息披露义务，上半年经营情况请以后续正式披露的半年报为准。交易信息汇总资金流向7月23日主力资金净流出152.65万元，占总成交额0.0%；游资资金净流出1092.85万元，占总成交额0.0%；散户资金净流入1245.5万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400001535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0082","600056","BK0010","BK0028","BK0250","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652211995","title":"中国医药（600056）披露子公司获得药品补充申请批准通知书，7月20日股价上涨1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652211995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652211995?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:22","pubTimestamp":1784557346,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，中国医药报收于9.61元，较前一交易日上涨1.59%，最新总市值为143.75亿元。近日，中国医药全资子公司天方药业有限公司收到国家药监局核准签发的布美他尼注射液《药品补充申请批准通知书》，该药品上市许可持有人由深圳格莱恩生物医药科技有限公司变更为天方药业。截至公告日，项目累计投入约146.52万元。国内已有46家生产企业拥有该药品批件，2025年全国销售额约26,233万元，2026年第一季度约4,263万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0175","BK0028","600056","BK0250","BK0188","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652230817","title":"每周股票复盘：中国医药（600056）子公司获依折麦布原料药批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2652230817","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652230817?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:15","pubTimestamp":1784398511,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，中国医药报收于9.46元，较上周的9.09元上涨4.07%。本周，中国医药7月17日盘中最高价报9.84元。中国医药当前最新总市值141.51亿元，在医药商业板块市值排名6/32，在两市A股市值排名1267/5199。截至公告日，天方药业在该药品原料和制剂累计投入约1,473.19万元。目前国内依折麦布原料药有26个登记号，其中18个状态为“A”。本次获批有助于公司拓展产品领域，完善心血管领域原料药布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0185","600056","BK0082","BK0175","BK0188","BK0028","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651029414","title":"中国医药(600056.SH)子公司化学原料药依折麦布上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2651029414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651029414?lang=zh_cn&edition=full","pubTime":"2026-07-16 15:56","pubTimestamp":1784188585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司天方药业有限公司收到国家药品监督管理局核准签发的依折麦布《化学原料药上市申请批准通知书》。该药品主要用于原发性高胆固醇血症、纯合子家族性高胆固醇血症(HoFH)、纯合子谷甾醇血症(或植物甾醇血症)。此次原料药的获批将进一步拓展公司的产品领域，完善心血管领域原料药产品布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0185","BK0082","BK0188","600056","BK0175","IPOS","BK0250","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651019168","title":"2025年度中国医药工业营收百强榜发布，齐鲁制药连续三年位列第三","url":"https://stock-news.laohu8.com/highlight/detail?id=2651019168","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651019168?lang=zh_cn&edition=full","pubTime":"2026-07-13 15:42","pubTimestamp":1783928549,"startTime":"0","endTime":"0","summary":"7月11日至12日，由中国医药工业信息中心等单位主办的第43届全国医药工业信息年会 & 2026北京·昌平生命科学论坛在北京召开。大会发布了备受行业关注的“2025年度中国医药工业主营业务收入前100位企业”以及“2026年中国医药研发产品线示范工业企业”“2026年中国医药工业企业社会责任优秀案例”等系列榜单。齐鲁制药集团第十一次跻身中国医药工业主营业务收入前100位企业，连续三年位居第三位。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783928491744277655","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["01477","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650902882","title":"美银证券：授权交易活跃料推动中国医药板块估值重评 上调信达生物(01801)目标价119.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650902882","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650902882?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:00","pubTimestamp":1783663206,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，中国医药行业授权交易活跃，加上企业持续推进研发创新，将有利于板块估值重评。该行指，信达生物宣布与礼来 就CDK4/6抑制剂Verzenios达成中国内地商业化协议，相应将2026至2028年收入预测上调3.3%、5.3%及4.7%，目标价由116.8港元上调至119.2港元，评级维持“买入”，认为公司商业产品组合丰富及内部研发能力稳健。另外，固生堂亦宣布收购沙河医院及北京弘阳医院权益，美银证券维持其“买入”评级及目标价32.6港元不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","161027","600056","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649455986","title":"瑞银：中国医药零售行业监管影响有限 降阿里健康(00241)目标价 维持京东健康(06618)的“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2649455986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649455986?lang=zh_cn&edition=full","pubTime":"2026-07-06 13:48","pubTimestamp":1783316938,"startTime":"0","endTime":"0","summary":"瑞银维持京东健康的“买入”评级，认为京东线上平台在用户及供应链层面都已建立竞争优势;维持阿里健康的“沽售”评级，2027至2029财年盈利预测下调5%，预测2026至2029财年收入及经调整纯利年均复合增长率分别为12%及5%。目标价由3.6港元下调至3.1港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600056","06618","00241","RETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649619322","title":"股市必读：中国医药（600056）7月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649619322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649619322?lang=zh_cn&edition=full","pubTime":"2026-07-06 03:31","pubTimestamp":1783279870,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，中国医药报收于9.12元，上涨1.11%，换手率1.05%，成交量15.74万手，成交额1.43亿元。董秘最新回复投资者： 第四届中国国际供应链促进博览会,中国医药北京公司与阿斯利康现场签署新一轮战略合作协议。公司严格按照监管要求履行信息披露义务，若有关事项达到披露标准，将及时发布公告。当日关注点交易信息汇总：7月3日中国医药主力资金净流出320.98万元，游资资金净流入277.11万元，散户资金净流入43.87万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600001223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0028","BK0010","BK0250","BK0082","BK0175","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648796523","title":"股市必读：中国医药（600056）7月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648796523","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648796523?lang=zh_cn&edition=full","pubTime":"2026-07-02 03:27","pubTimestamp":1782934030,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，中国医药报收于8.96元，上涨2.4%，换手率1.11%，成交量16.53万手，成交额1.46亿元。董秘最新回复投资者： 第24届世界制药原料中国展，团队以专业素养与饱满风貌，接待来自中亚、印度、非洲、拉美等多个地区的海内外客户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200001678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0082","600056","BK0175","BK0250","BK0185","BK0010","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645934598","title":"仁和药业：引进外资共同开发创新药是当前中国医药产业从“跟随创新”向“源头创新”跃升的关键路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2645934598","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645934598?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:21","pubTimestamp":1782289276,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！贵公司是否有意向引进外资而共同开发创新药吗？谢谢！仁和药业回复：尊敬的投资者，您好！引进外资共同开发创新药是当前中国医药产业从“跟随创新”向“源头创新”跃升的关键路径，已形成“资本+技术+市场”双向赋能的良性循环。公司持积极开放的态度。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400028909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0175","BK0188","BK0239","BK1161","BK0028","BK0097","BK0250","600056","BK0185","159992","BK0082","BK0010","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645202583","title":"太极集团：公司实际控制人中国医药集团有限公司间接持有公司30.12%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645202583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645202583?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:57","pubTimestamp":1782122231,"startTime":"0","endTime":"0","summary":"证券之星消息，太极集团(600129)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：国药集团控股比例是否已突破30%？是上次回购被动突破的么？太极集团回复：您好！感谢对公司的关注。公司实际控制人中国医药集团有限公司间接持有公司30.12%的股份，敬请详见公司披露的定期报告。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0250","BK0082","BK0185","BK0175","BK0028","BK0113","600129","600056","BK0010","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644066360","title":"每周股票复盘：中国医药（600056）拟每股派现0.07525元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644066360","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644066360?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:34","pubTimestamp":1781897652,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，中国医药报收于9.09元，较上周的9.15元下跌0.66%。本周，中国医药6月15日盘中最高价报9.28元。本周关注点公司公告汇总：中国医药拟每股派发现金红利0.07525元（含税）。公司公告汇总中国医药健康产业股份有限公司2025年年度权益分派实施公告：每股派发现金红利0.07525元（含税），股权登记日为2026年6月25日，除权（息）日和现金红利发放日均为2026年6月26日。本次利润分配以公司总股本1,495,879,748股为基数，共派发现金红利112,564,951.04元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000002092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0175","BK0028","600056","BK0250","BK0188","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644747833","title":"中国医药（600056）披露2025年年度权益分派实施公告，6月17日股价上涨0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644747833","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644747833?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:55","pubTimestamp":1781708114,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，中国医药报收于9.1元，较前一交易日上涨0.22%，最新总市值为136.13亿元。该股当日开盘9.09元，最高9.12元，最低9.0元，成交额达6747.25万元，换手率为0.5%。近日，中国医药健康产业股份有限公司发布《2025年年度权益分派实施公告》：每股派发现金红利0.07525元（含税），股权登记日为2026年6月25日，除权（息）日和现金红利发放日均为2026年6月26日。本次利润分配以公司总股本1,495,879,748股为基数，共派发现金红利112,564,951.04元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0175","BK0028","BK0188","600056","BK0250","BK0185","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100904","title":"中国医药最新公告：子公司天方药业获阿哌沙班原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100904","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100904?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:09","pubTimestamp":1780909783,"startTime":"0","endTime":"0","summary":"中国医药(600056.SH)公告称，公司下属全资子公司天方药业收到国家药监局核准签发的阿哌沙班《化学原料药上市申请批准通知书》。该药品主要用于预防髋关节或膝关节置换术后静脉血栓栓塞事件。截至公告日，天方药业在该药品累计投入约1224万元。此次获批将进一步拓展公司产品领域，但未来销售可能受市场环境等不确定因素影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0175","BK0188","BK0028","BK0185","600056","BK0010","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640159152","title":"艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640159152","media":"智通财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640159152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:53","pubTimestamp":1780574025,"startTime":"0","endTime":"0","summary":"本次权益变动完成后，国药集团(北京)科技创新研究院有限公司将成为公司控股股东，公司实际控制人将变更为中国医药集团有限公司。公司股票于2026年6月5日开市起复牌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2460026573.USD","300685","BK0185","BK0250","600056","BK0010","BK0239","BK0082","BK0188","BK0042","BK0175","BK0028","IE0005HP3H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640947225","title":"股市必读：中国医药（600056）6月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640947225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640947225?lang=zh_cn&edition=full","pubTime":"2026-06-03 01:45","pubTimestamp":1780422315,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，中国医药报收于9.87元，下跌0.8%，换手率0.79%，成交量11.75万手，成交额1.17亿元。董秘最新回复投资者： 请问公司，公司董秘在4月2日回答关于公司创新药的问答。公司重视投资者沟通交流，珍视投资者的宝贵意见，通过多种合规渠道与市场保持良好互动及有效沟通。股价波动受宏观经济、市场情绪、行业周期等多重因素影响，敬请注意投资风险。当日关注点来自交易信息汇总：6月2日主力资金净流出1419.71万元，占总成交额12.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300001928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0175","BK0185","BK0188","BK0028","600056","BK0250","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640391669","title":"中国医药：公司目前经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2640391669","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640391669?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:51","pubTimestamp":1780390289,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药06月02日在投资者关系平台上答复投资者关心的问题。公司目前经营正常，积极推进战略转型和动能转换，持续探索新型业务模式，加快构建新发展格局。公司始终坚持将股东利益放在重要位置，连续三年制定“提质增效重回报”行动方案，围绕提高经营质效、治理质效、信披质效和回报投资者质效等多方面开展工作，推动公司高质量发展，以更好的回报股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200031588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0250","BK0010","BK0028","BK0082","600056","BK0175","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604167","title":"每周股票复盘：中国医药（600056）子公司卡络磺钠注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604167","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604167?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:36","pubTimestamp":1780169773,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，中国医药报收于9.9元，较上周的9.84元上涨0.61%。本周，中国医药5月27日盘中最高价报9.99元。公司公告汇总中国医药全资子公司海南通用康力制药有限公司收到国家药监局核准签发的三份卡络磺钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。卡络磺钠注射液适用于泌尿系统、上消化道、呼吸道和妇产科出血疾病，以及手术出血的预防与治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0175","BK0028","BK0188","600056","BK0250","BK0185","BK0010"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785304334165,"stockEarnings":[{"period":"1week","weight":-0.0106},{"period":"1month","weight":0.0897},{"period":"3month","weight":-0.0932},{"period":"6month","weight":-0.1458},{"period":"1year","weight":-0.131},{"period":"ytd","weight":-0.0871}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0716},{"period":"6month","weight":-0.0829},{"period":"1year","weight":0.0599},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"129001人(较上一季度减少1.83%)","perCapita":"11591股","listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","registeredCapital":"149587万元","survey":" 中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是化学制剂、诊断药品及试剂、医用耗材、医疗器械、特医产品、医美产品、中成药、中药饮片、配方颗粒、生物制剂、营养保健品。","listedPrice":7.02},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国医药,600056,中国医药股票,中国医药股票老虎,中国医药股票老虎国际,中国医药行情,中国医药股票行情,中国医药股价,中国医药股市,中国医药股票价格,中国医药股票交易,中国医药股票购买,中国医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}